The safety of thiazolidinediones

Bibliography

• Statistics Clearinghouse, NIH/NIDDK
   Google Scholar
• Group, U.P.D.S.U. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;354:837-53
   Google Scholar
• Group, U.P.D.S.U. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
   PubMed Web of Science ®Google Scholar
• Yki-jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18
   PubMed Web of Science ®Google Scholar
• Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 2001;70:341-67
   PubMed Web of Science ®Google Scholar
• Dubois M, Pattau F, Kerr-Conte J, Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells. Diabetologia 2000;43(9):1165-9
   PubMed Web of Science ®Google Scholar
• Berger JP, Petro AE, Macnaul KL, Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Mol Endocrinol 2003;17(4):662-76
   PubMed Web of Science ®Google Scholar
• Maeda N, Shimomura I, Kishida K, Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002;8(7):731-7
   PubMed Web of Science ®Google Scholar
• Matsuda M, Shimomura I, Sata M, Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 2002;277(40):37487-91
   PubMed Web of Science ®Google Scholar
• Peraldi P, Spiegelman B. TNF-alpha and insulin resistance: summary and future prospects. Mol Cell Biochem 1998;182(1-2):169-75
   PubMed Web of Science ®Google Scholar
• Steppan CM, Bailey ST, Bhat S, The hormone resistin links obesity to diabetes. Nature 2001;409(6818):307-12
   PubMed Web of Science ®Google Scholar
• Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000;49(10):497-505
   PubMed Web of Science ®Google Scholar
• Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002;53:409-35
   PubMed Web of Science ®Google Scholar
• Barbier O, Torra IP, Duguay Y, Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2002;22(5):717-26
   PubMed Web of Science ®Google Scholar
• Picard F, Auwerx J. PPAR(gamma) and glucose homeostasis. Annu Rev Nutr 2002;22:167-97
   PubMed Web of Science ®Google Scholar
• Unger R. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Diabetes 1995;44:863-9
   PubMed Web of Science ®Google Scholar
• Shulman G. Cellular mechanisms of insulin resistance. J Clin Invest 2000;106:171-6
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Marx N, Pfutzner A, Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular-risk patients with elevated high sensitivity c-reactive protein: the PIOSTAT study. J Am Coll Cardiol 2007;49(3):290-7
   PubMed Web of Science ®Google Scholar
• Fernandez M, Triplitt C, Wajeberg E, Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetes patients improves vascular dysfunction by different mechanisms. Diabetes Care 2008;31:121-7
   PubMed Web of Science ®Google Scholar
• Goldberg R, Kendall DM, Deeg MA, A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-54
   PubMed Web of Science ®Google Scholar
• Staels B, Fruchart J. Therapeutic roles of peroxisome proliferator-activated receptor agonist. Diabetes 2005;54(8):2460-70
   PubMed Web of Science ®Google Scholar
• Tolman K, Fonseca V, Dalpiaz A, Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007;30(3):734-43
   PubMed Web of Science ®Google Scholar
• Tolman K, Chandramouli J. Hepatotoxicity of the thiazolidinediones. Clin Liver Dis 2003;7:369-79
   PubMedGoogle Scholar
• Bourgeois FT, Murthy S, Mandl KD. Outcome Reporting Among Drug Trials Registered in ClinicalTrials.gov. Ann Intern Med 2010;153(3):158-66
   PubMed Web of Science ®Google Scholar
• Angell M. Big Pharma, Bad Medicine; 2009
   Google Scholar
• Buchanan T, Xiang AH, Peters RK, Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51:2796-803
   PubMed Web of Science ®Google Scholar
• Ghazzi M, Perez JE, Antonucci TK, Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 1997;46:433-9
   PubMed Web of Science ®Google Scholar
• Sung B, Izzo Jr JL, Dandona P, Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension 1999;34:83-8
   PubMed Web of Science ®Google Scholar
• Schwart S, Raskin P, Fonseca V, Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med 1998;338:861-6
   PubMed Web of Science ®Google Scholar
• Kruszynska Y, Yu JG, Olefsky JM, Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 2000;49:633-9
   PubMed Web of Science ®Google Scholar
• Azziz R, Ehrmann D, Legro RS, Troglitazone improves ovulation and hirsutism in polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001;86:1626-32
   PubMed Web of Science ®Google Scholar
• Arioglu E, Duncan-Morin J, Sebring N, Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000;133(263-274):263
   PubMedGoogle Scholar
• Willi S, Kennedy A, Wallace P, Troglitazone antagonizes metabolic effects of glucocorticoids in humans: effects on glucose tolerance, insulin sensitivity, suppression of free fatty acids, and leptin. Diabetes 2002;51:2895-902
   PubMed Web of Science ®Google Scholar
• Herrine SK, Choudhary C. Severe hepatotoxicity associated with troglitazone. Ann Intern Med 1999;130(2):163-4
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA, Isley WL, Oki JC, Troglitazone-induced hepatic failure leading to liver transplantation. A case report. Ann Intern Med 1998;129(1):38-41
   PubMed Web of Science ®Google Scholar
• Shibuya A, Watanabe M, Fujita Y, An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care 1998;21(12):2140-3
   PubMed Web of Science ®Google Scholar
• Misbin RI. Troglitazone-associated hepatic failure. Ann Intern Med 1999;130(4 Pt 1):330
   PubMed Web of Science ®Google Scholar
• Vella A, de Groen PC, Dinneen SF. Fatal hepatotoxicity associated with troglitazone. Ann Intern Med 1998;129(12):1080
   PubMed Web of Science ®Google Scholar
• Mathai K, Reichheld J, Banner BF, Hepatotoxicity due to troglitazone; report of two cases and review of adverse effect reports to the United States Food and Drug Administration. Am J Gastroenterol 2000;95:272-6
   PubMed Web of Science ®Google Scholar
• Board E.a.M.D.A. US Food and Drug Administration. In: Presented at the Endocrinologic and Metabolic Drugs Advisory Board; 1999
   Google Scholar
• Graham D, Green L, Senior JR, Troglitazone-induced liver failure: a case study. Am J Med 2002;114:299-306
   Web of Science ®Google Scholar
• Ravinuthala R, Nori U. Rosiglitazone toxicity. Ann Intern Med 2000;133:658
   PubMed Web of Science ®Google Scholar
• Al-Jalman J, Arjomand H, Kemp DG, Hepatocellular injury in a patient receiving rosiglitazone. Ann Intern Med 2000;132(121-124):121
   PubMedGoogle Scholar
• Maeda K. Hepatocellular injury in a patient receiving pioglitazone. Ann Intern Med 2002;135:306
   Web of Science ®Google Scholar
• Chase M. Pioglitazone-associated fulminant hepatic failure. Am J Gastroenterol 2002;97:502
   PubMed Web of Science ®Google Scholar
• May L, Letkowich JH, Kram MT, Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann Intern Med 2002;136:449-52
   PubMed Web of Science ®Google Scholar
• Gouda HE, Khan A, Schwartz J, Liver failure in a patient treated with long-term rosiglitazone therapy. Am J Med 2001;111(7):584-5
   PubMed Web of Science ®Google Scholar
• Zawadzki J, Green L, Graham B. Thioglitazone-associated 15-month post-marketing hepatotoxicity. FDA science forum [article online]. Available from: http://www.cfsan.fda.gov∼frf/forumoz/a187ab4.htm. [Accessed 5 February 2002]
   Google Scholar
• Chan K, Truman A, Gurwitz J, A cohort study of the incidence of acute liver failure in diabetic patients treated with hypoglycemic agents. Amer Assoc for it Study of Liver Disease Abstract; 2001 p. 1186
   Google Scholar
• Belfort R, Harrison SA, Brown K, A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355(22):2297-307
   PubMed Web of Science ®Google Scholar
• Aithal GP, Thomas JA, Kaye PV, Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008;135:1178-84
   Google Scholar
• Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003;38(4):1008-17
   PubMed Web of Science ®Google Scholar
• Promrat K, Lutchman G, Uwaifo GI, A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39(1):188-96
   PubMed Web of Science ®Google Scholar
• Graham D, Domlard CR, Shatin D, Liver enzyme monitoring in patients treated with troglitazone. JAMA 2001;286:831-3
   PubMed Web of Science ®Google Scholar
• Tolman K. Lovastatin and the liver. Am J Cardiol 2002;89:1374-80
   PubMed Web of Science ®Google Scholar
• Gu K, Cowie C, Harris M. Mortality in adults with and without diabetes in a national cohort of the US population. Diabetes Care 1998;21:1138-45
   PubMed Web of Science ®Google Scholar
• Selvin E, Marinopoulos S, Berkenblit G, Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004;141:421-31
   PubMed Web of Science ®Google Scholar
• Goff DJ, Gerstein HC, Ginsberg HN, Prevention of cardiovascular disease in persons with type 2 diabetes mellitus; current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99:4i-20i
   PubMed Web of Science ®Google Scholar
• Group, U.P.D.S.U. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Qayyum R, Adomaityte J. A meta-analysis of the effect of thiazolidinediones on blood pressure. J Clin Hypertens 2006;8(1):19-28
   Google Scholar
• Qayyum R, Adomaityte J. Meta-analysis of the effect of thiazolidinediones on serum C-reactive protein levels. Am J Cardiol 2006;97(5):655-8
   PubMed Web of Science ®Google Scholar
• Mazzone T, Meyer PM, Feinstein SB, Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006;296(21):2572-81
   PubMed Web of Science ®Google Scholar
• Singh S, Loke Y, Furberg C. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 2007;30:2148-53
   PubMed Web of Science ®Google Scholar
• Gerstein H, Yusuf S, Bosch J. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006;368(9541):1096-105
   PubMed Web of Science ®Google Scholar
• Dormandy J, Charbonnel B, Eckland DJ, Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): a randomized controlled trial. Lancet 2005;366(9493):1279-89
   PubMed Web of Science ®Google Scholar
• Nissen S, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356(24):2457-71
   PubMed Web of Science ®Google Scholar
• Gerrits CM, Bhattacharya M, Manthena S, A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf 2007;16(10):1065-71
   PubMed Web of Science ®Google Scholar
• Walker AM, Koro CE, Landon J. Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007. Pharmacoepidemiol Drug Saf 2008;17(8):760-8
   PubMed Web of Science ®Google Scholar
• Winkelmayer WC, Setoguchi S, Levin R, Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med 2008;168(21):2368-75
   PubMed Web of Science ®Google Scholar
• Dormuth CR, Maclure M, Carney G, Rosiglitazone and myocardial infarction in patients previously prescribed metformin. PLoS ONE 2009;4(6):e6080
   PubMedGoogle Scholar
• Juurlink DN, Gomes T, Lipscombe LL, Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ 2009;339:b2942
   PubMed Web of Science ®Google Scholar
• Ziyadeh N, McAfee AT, Koro C, The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database. Clin Ther 2009;31(11):2665-77
   PubMed Web of Science ®Google Scholar
• Brownstein JS, Murphy SN, Goldfine AB, Rapid identification of myocardial infarction risk associated with diabetes medications using electronic medical records. Diabetes Care 2010;33(3):526-31
   PubMed Web of Science ®Google Scholar
• Habib ZA, Tzogias L, Havstad SL, Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis. Pharmacoepidemiol Drug Saf 2009;18(6):437-47
   PubMed Web of Science ®Google Scholar
• Kendall C, Wooltorton E. Rosiglitazone (Avandia) and macular edema. CMAJ 2006;174(5):2427-43
   Google Scholar
• Lincoff A, Wolski K, Nicholls SJ, Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;12(298):1180-8
   Google Scholar
• Dormandy J, Charbonnel B, Eckland DJ, Secondary prevention of macrovascular events in patients with type 2 diabetes in the proactive study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomized controlled trial. Lancet 2005;366:1279-89
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298(10):1189-95
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline Rosiglitazone studies
   Google Scholar
• Pantalone KM, Kattan MW, Yu C, The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol 2009;46(2):145-54
   PubMed Web of Science ®Google Scholar
• Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010;304(4):411-18
   PubMed Web of Science ®Google Scholar
• ACTOS. Pioglitazone hydrochloride. Takeda Pharmaceuticals America, Inc., Deerfield, IL; 2008
   Google Scholar
• Avandia. Rosiglitazone. GlaxoSmithKline, Research Triangle Park, NC; 2008
   Google Scholar
• Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007;370(9593):1129-36
   PubMed Web of Science ®Google Scholar
• Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004;164(19):2097-104
   PubMed Web of Science ®Google Scholar
• Rosiglitazone (Avandia) revisited. Med Lett Drugs Ther 2010;52(1333):17
   Web of Science ®Google Scholar
• Available from: http://www.fda.gov/downloads/Drugs/Guidances/UCM071627
   Google Scholar
• Woodcock J, Sharfstein JM, Harrisberg M. Regulatory action on rosiglitazone by the US Food and Drug Administration. Available from: http://www.nejm.org [Cited 23 September 2010]
   Google Scholar
• Available from: www.ema.europa.eu/docs/en GB/document library/press [Cited September 2010]
   Google Scholar
• Masoudi FA, Wang Y, Inzucchi SE, Metformin and thiozolidinediones use in Medicare patients with heart failure. JAMA 2002;106:679-84
   Google Scholar
• Nesto RW, Zarich S. Acute myocardial infarction in diabetes mellitus: lessons learned from ACE inhibition. Circulation 1998;97(1):12-15
   PubMed Web of Science ®Google Scholar
• Devereux RB, Roman MJ, Paranicas M, Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 2000;101(19):2271-6
   PubMed Web of Science ®Google Scholar
• Fang ZY, Yuda S, Anderson V, Echocardiographic detection of early diabetic myocardial disease. J Am Coll Cardiol 2003;41(4):611-17
   PubMed Web of Science ®Google Scholar
• Nichols GA, Hillier TA, Erbey JR, Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001;24(9):1614-19
   PubMed Web of Science ®Google Scholar
• ACTOS. Pioglitazone hydrochloride. Takeda Pharmaceuticals America, Inc., Lincolnshire, Ill; 2002
   Google Scholar
• Belcher G, Michel J. Tolerability profile of pioglitazone in combination with a sulfonylurea or metformin in controlled clinical trials. Diabetes 2001;50(Suppl 2):A416
   Google Scholar
• Aronoff S. Adverse events with pioglitazone. Diabetes 2000;49(Suppl I):A340-1
   PubMedGoogle Scholar
• Raskin P, Rendell M, Riddle MC, A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001;24(7):1226-32
   PubMed Web of Science ®Google Scholar
• Rubin C, Egan J, Schacider R. Combination therapy with pioglitazone and insulin in patients with type 2 diabetes. Diabetes 1999;29(Suppl I):A110
   Google Scholar
• Nesto RW, Bell D, Bonow RO, Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003;108(23):2941-8
   PubMed Web of Science ®Google Scholar
• Bando Y, Ushiogi Y, Okafuji K, Troglitazone combination therapy in obese type 2 diabetic patients poorly controlled with alpha-glucosidase inhibitors. J Int Med Res 1999;27(2):53-64
   PubMed Web of Science ®Google Scholar
• Yoshimoto T, Naruse M, Nishikawa M, Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol 1997;272(6 Pt 1):E989-96
   PubMed Web of Science ®Google Scholar
• Walker AB, Naderali EK, Chattington PD, Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes 1998;47(5):810-14
   PubMed Web of Science ®Google Scholar
• ACTOS. Pioglitazone hydrochloride. Takeda Pharmaceuticals America, Inc., Lincolnshire, Ill; 2000
   Google Scholar
• Karter A, Liu JY, Moffet HH, Pioglitazone utilization and congestive heart failure among diabetic patients initiating new diabetes therapies., in The American Diabetes Association and American Heart Associations' Working Group on Glitazones and Heart Disease. Chicago, Ill; 2002
   Google Scholar
• Ghazzi MN, Perez JE, Antonucci TK, Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes 1997;46(3):433-9
   PubMed Web of Science ®Google Scholar
• Schneider R, Shaffer S. Long-term echocardiographic assessment in patients with type 2 diabetes mellitus treated with pioglitazone. Diabetes 2000;49(Suppl 1):A124
   Google Scholar
• St John Sutton M, Rendell M, Dandona P, A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002;25(11):2058-64
   PubMed Web of Science ®Google Scholar
• Yue TL, Chen J, Bao W, In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 2001;104(21):2588-94
   PubMed Web of Science ®Google Scholar
• Shiomi T, Tsutsui H, Hayashidani S, Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002;106(24):3126-32
   PubMed Web of Science ®Google Scholar
• Mitri J, Hamdy O. Diabetes medications and body weight. Expert Opin Drug Saf 2009;8(5):573-84
   PubMed Web of Science ®Google Scholar
• Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf 2007;30(12):1127-42
   PubMed Web of Science ®Google Scholar
• Wilding J. Thiazolidinediones, insulin resistance and obesity: finding a balance. Int J Clin Pract 2006;60(10):1272-80
   PubMed Web of Science ®Google Scholar
• Jacob AN, Salinas K, Adams-Huet B, Weight gain in type 2 diabetes mellitus. Diabetes Obes Metab 2007;9(3):386-93
   PubMed Web of Science ®Google Scholar
• Ratziu V, Giral P, Jacqueminet S, Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008;135(1):100-10
   PubMed Web of Science ®Google Scholar
• Kelly IE, Han TS, Walsh K, Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999;22(2):288-93
   PubMed Web of Science ®Google Scholar
• Nakamura T, Funahashi T, Yamashita S, Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation – double-blind placebo-controlled trial. Diabetes Res Clin Pract 2001;54(3):181-90
   PubMed Web of Science ®Google Scholar
• Katoh S, Hata S, Matsushima M, Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy – a randomized controlled trial. Metabolism 2001;50(4):414-17
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol 2003;38(4):434-40
   PubMed Web of Science ®Google Scholar
• Balas B, Belfort R, Harrison SA, Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. J Hepatol 2007;47(4):565-70
   PubMed Web of Science ®Google Scholar
• Ruano G, Bernene J, Windemuth A, Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone. Clin Chim Acta 2009;400(1-2):48-55
   PubMed Web of Science ®Google Scholar
• Kawai T, Funae O, Shimada A, Effects of pretreatment with low-dose metformin on metabolic parameters and weight gain by pioglitazone in Japanese patients with type 2 diabetes. Intern Med 2008;47(13):1181-8
   PubMed Web of Science ®Google Scholar
• Negishi M, Shimomura K, Proks P, Alpha glucosidase inhibitor voglibose can prevent pioglitazone-induced body weight gain in Type 2 diabetic patients. Br J Clin Pharmacol 2008;66(2):318-19
   PubMed Web of Science ®Google Scholar
• Asnani S, Richard BC, Desouza C, Is weight loss possible in patients treated with thiazolidinediones? Experience with a low-calorie diet. Curr Med Res Opin 2003;19(7):609-13
   PubMed Web of Science ®Google Scholar
• Bodmer M, Meier C, Kraenzlin ME, Risk of fractures with glitazones: a critical review of the evidence to date. Drug Saf 2009;32(7):539-47
   PubMed Web of Science ®Google Scholar
• Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009;180(1):32-9
   PubMed Web of Science ®Google Scholar
• Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int 2008;19(2):129-37
   PubMed Web of Science ®Google Scholar
• Meier C, Kraenzlin ME, Bodmer M, Use of thiazolidinediones and fracture risk. Arch Intern Med 2008;168(8):820-5
   PubMed Web of Science ®Google Scholar
• Glintborg D, Anderson M, Hagen C, Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 2008;93(5):1696-701
   PubMed Web of Science ®Google Scholar
• Habib ZA, Havstad SL, Wells K, Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010;95(2):592-600
   PubMed Web of Science ®Google Scholar
• Jones SG, Momin SR, Good MW, Distal upper and lower limb fractures associated with thiazolidinedione use. Am J Manag Care 2009;15(8):491-6
   PubMed Web of Science ®Google Scholar
• Dormuth CR, Carney G, Carleton B, Thiazolidinediones and fractures in men and women. Arch Intern Med 2009;169(15):1395-402
   PubMed Web of Science ®Google Scholar
• Solomon DH, Cadarette SM, Choudhry NK, A cohort study of thiazolidinediones and fractures in older adults with diabetes. J Clin Endocrinol Metab 2009;94(8):2792-8
   PubMed Web of Science ®Google Scholar
• Rosen CJ. Revisiting the rosiglitazone story – lessons learned. N Engl J Med 2010;363(9):803-6
   PubMed Web of Science ®Google Scholar